ANROHealthcare · BiotechnologyThe 11 Wall Street analysts covering Alto Neuroscience, Inc. hold a median 12-month price target of $37 — +63.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 14 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Alto Neuroscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (88): The shares have been drifting up relative to others.
Growth (37): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ANRO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +63.3% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $50 → $55 |
| 13 Aug 2026 | BTIG | Maintains | Buy | $28 → $37 |
| 13 Aug 2026 | Wedbush | Maintains | Neutral | $24 → $26 |
| 18 May 2026 | Baird | Maintains | Outperform | $38 → $36 |
| 18 May 2026 | Baird | Maintains | Outperform | — |
| 14 May 2026 | Wedbush | Maintains | Neutral | $21 → $24 |
| 14 May 2026 | Wedbush | Maintains | Neutral | — |
| 11 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $50 |
| 11 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 May 2026 | HC Wainwright& Co. | Reiterates | Buy | — |
| 22 Apr 2026 | Chardan Capital | Maintains | Buy | — |
| 2 Apr 2026 | Baird | Maintains | Outperform | — |
| 2 Apr 2026 | Chardan Capital | Maintains | Buy | — |
| 2 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2026 | Jones Trading | Maintains | Buy | — |
| 2 Apr 2026 | Wedbush | Maintains | Neutral | — |
| 18 Mar 2026 | Baird | Maintains | Outperform | — |
| 17 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 17 Mar 2026 | Wedbush | Maintains | Neutral | — |
| 17 Feb 2026 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANRO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Oct 2026, Alto Neuroscience, Inc. returned +270.9% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 27% of US stocks
Cheaper than 83% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 16% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alto Neuroscience, Inc. has a market value of $851.9M and an enterprise value of $631.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$84.2M.
Free cash flow in the twelve months to 30 June 2026: −$68.8M, after $556K of capital spending.
Trailing P/E: −9.9×; forward P/E: −6.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alto Neuroscience, Inc. employs 68 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alto Neuroscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alto Neuroscience is advancing its depression drug pipeline, with key study results for ALTO-207, ALTO-300 and ALTO-100 expected in 2027.
Why it matters — ANRO watchers may follow the 2027 study results as milestones in the company's depression drug pipeline.
Alto Neuroscience announced that members of its management team will participate in the H.C. Wainwright 28th Annual Global Healthcare Conference, scheduled for September 14-16, 2026, featuring a fireside chat and one-on-one meetings.
Why it matters — ANRO watchers would care because the company's participation in investor conferences provides an opportunity for management to present its clinical-stage precision medicine programs to the investment community.
Alto Neuroscience announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Smith will continue to lead the finance function and oversee corporate strategy and business development, reporting to founder and CEO Amit Etkin.
Why it matters — This leadership promotion signals continued stability in Alto's finance and corporate strategy functions as the clinical-stage company advances its pipeline.
Alto Neuroscience reported its financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. The company noted that the second quarter strengthened the case for ALTO-207 and management's conviction in its opportunity.
Why it matters — ANRO watchers would care because the update reinforces management confidence in lead candidate ALTO-207 and signals continued pipeline progress for a clinical-stage neuropsychiatric precision-medicine company.
A Seeking Alpha article highlights Alto Neuroscience's ALTO-207, a pramipexole/ondansetron combination for treatment-resistant depression, with phase 2b topline data expected in 2H 2027 and possible phase 3 initiation by early 2027. The piece notes the company's strong cash reserves and diversified, biomarker-driven pipeline, even after ALTO-100's phase 2b failure in MDD, as supporting factors for its positive rating on the stock.
Why it matters — ANRO watchers would care because the ALTO-207 timeline and pipeline breadth are central to the company's outlook after the ALTO-100 setback.
The 11 Wall Street analysts covering Alto Neuroscience, Inc. have a median 12-month price target of $37, with estimates ranging from $26 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Alto Neuroscience, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alto Neuroscience, Inc. 60 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Alto Neuroscience, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +63.3% from the last close, and Ticker Nerd's factor model ranks Alto Neuroscience, Inc. 60 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alto Neuroscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $55 over the next 12 months.
Alto Neuroscience, Inc. returned +270.9% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders.
The most recent item we track (Zacks Investment Research, 14 Oct 2026): "Here's Why You Should Add ANRO Stock to Your Portfolio Now". Alto Neuroscience is advancing its depression drug pipeline, with key study results for ALTO-207, ALTO-300 and ALTO-100 expected in 2027.
Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders. Alto Neuroscience applies its Precision Psychiatry Platform to analyze brain biomarkers, EEG activity, neurocognitive assessments, wearable data, and other patient-specific measures to help match therapies with the people most likely to benefit. Its current pipeline includes drug candidates targeting bipolar depression, major depressive disorder, treatment-resistant depression, schizophrenia, and related cognitive and mood disorders. The company is centered on personalized psychiatry, using biology-driven research to support the development of novel psychiatric treatments. Alto Neuroscience is headquartered in Mountain View, California, and its work today is concentrated on advancing clinical-stage programs for mental health conditions through biomarker-guided drug development.
CEO Dr. Amit Etkin M.D., Ph.D. · 68 employees · United States · https://www.altoneuroscience.com
